Pierre Fabre's vinflunine receives an EU positive opinion in bladder cancer
This article was originally published in Scrip
Pierre Fabre's new vinca alkaloid anticancer, Javlor (vinflunine ditartrate, 25mg/ml), has received a positive opinion from the EU's CHMP, for the second-line treatment of transitional cell carcinoma of the urothelium.
You may also be interested in...
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.